The GLP-1 Effect: A Game-Changer or Silent Threat?
The Meteoric Rise of GLP-1 Therapies The pharmaceutical sector is undergoing a profound transformation, with GLP-1 receptor agonists (GLP-1 RAs) emerging as a leading treatment option for type 2 diabetes and obesity. Medications such as semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) have rapidly achieved blockbuster status, with global market projections exceeding… Continue reading The GLP-1 Effect: A Game-Changer or Silent Threat?